Search

Your search keyword '"van der Kouwe, Emiel"' showing total 19 results
Start Over Author "van der Kouwe, Emiel"
19 results on '"van der Kouwe, Emiel"'

1. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS

Author

Bauer, Karin, Machherndl-Spandl, Sigrid, Kazianka, Lukas, Sadovnik, Irina, Gültekin, Sinan, Suessner, Susanne, Proell, Johannes, Lauf, Jeroen, Hoermann, Gregor, Eisenwort, Gregor, Häfner, Norman, Födermayr-Mayrleitner, Mathilde, Schmolke, Ann-Sofie, van der Kouwe, Emiel, Platzbecker, Uwe, Lion, Thomas, Weltermann, Ansgar, Zach, Otto, Webersinke, Gerald, Germing, Ulrich, Gabriel, Christian, Sperr, Wolfgang R., Béné, Marie C., Staber, Philipp B., Bettelheim, Peter, and Valent, Peter

Published
2023
Full Text
View/download PDF

2. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML

Author

Trinh, Bon Q., Ummarino, Simone, Zhang, Yanzhou, Ebralidze, Alexander K., Bassal, Mahmoud A., Nguyen, Tuan M., Heller, Gerwin, Coffey, Rory, Tenen, Danielle E., van der Kouwe, Emiel, Fabiani, Emiliano, Gurnari, Carmelo, Wu, Chan-Shuo, Angarica, Vladimir Espinosa, Yang, Henry, Chen, Sisi, Zhang, Hong, Thurm, Abby R., Marchi, Francisco, Levantini, Elena, Staber, Philipp B., Zhang, Pu, Voso, Maria Teresa, Pandolfi, Pier Paolo, Kobayashi, Susumu S., Chai, Li, Di Ruscio, Annalisa, and Tenen, Daniel G.

Published
2021
Full Text
View/download PDF

3. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

Author

Snijder, Berend, Vladimer, Gregory I, Krall, Nikolaus, Miura, Katsuhiro, Schmolke, Ann-Sofie, Kornauth, Christoph, Lopez de la Fuente, Oscar, Choi, Hye-Soo, van der Kouwe, Emiel, Gültekin, Sinan, Kazianka, Lukas, Bigenzahn, Johannes W, Hoermann, Gregor, Prutsch, Nicole, Merkel, Olaf, Ringler, Anna, Sabler, Monika, Jeryczynski, Georg, Mayerhoefer, Marius E, Simonitsch-Klupp, Ingrid, Ocko, Katharina, Felberbauer, Franz, Müllauer, Leonhard, Prager, Gerald W, Korkmaz, Belgin, Kenner, Lukas, Sperr, Wolfgang R, Kralovics, Robert, Gisslinger, Heinz, Valent, Peter, Kubicek, Stefan, Jäger, Ulrich, Staber, Philipp B, and Superti-Furga, Giulio

Published
2017
Full Text
View/download PDF

4. Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, primary, Vladimer, Gregory I., primary, Bayer, Günther, primary, Bergmann, Michael, primary, Eder, Sandra, primary, Eichner, Ruth, primary, Erl, Martin, primary, Esterbauer, Harald, primary, Exner, Ruth, primary, Felsleitner-Hauer, Verena, primary, Forte, Maurizio, primary, Gaiger, Alexander, primary, Geissler, Klaus, primary, Greinix, Hildegard T., primary, Gstöttner, Wolfgang, primary, Hacker, Marcus, primary, Hartmann, Bernd Lorenz, primary, Hauswirth, Alexander W., primary, Heinemann, Tim, primary, Heintel, Daniel, primary, Hoda, Mir Alireza, primary, Hopfinger, Georg, primary, Jaeger, Ulrich, primary, Kazianka, Lukas, primary, Kenner, Lukas, primary, Kiesewetter, Barbara, primary, Krall, Nikolaus, primary, Krajnik, Gerhard, primary, Kubicek, Stefan, primary, Le, Trang, primary, Lubowitzki, Simone, primary, Mayerhoefer, Marius E., primary, Menschel, Elisabeth, primary, Merkel, Olaf, primary, Miura, Katsuhiro, primary, Müllauer, Leonhard, primary, Neumeister, Peter, primary, Noesslinger, Thomas, primary, Ocko, Katharina, primary, Öhler, Leopold, primary, Panny, Michael, primary, Pichler, Alexander, primary, Porpaczy, Edit, primary, Prager, Gerald W., primary, Raderer, Markus, primary, Ristl, Robin, primary, Ruckser, Reinhard, primary, Salamon, Julius, primary, Schiefer, Ana-Iris, primary, Schmolke, Ann-Sofie, primary, Schwarzinger, Ilse, primary, Selzer, Edgar, primary, Sillaber, Christian, primary, Skrabs, Cathrin, primary, Sperr, Wolfgang R., primary, Srndic, Ismet, primary, Thalhammer, Renate, primary, Valent, Peter, primary, van der Kouwe, Emiel, primary, Vanura, Katrina, primary, Vogt, Stefan, primary, Waldstein, Cora, primary, Wolf, Dominik, primary, Zielinski, Christoph C., primary, Zojer, Niklas, primary, Simonitsch-Klupp, Ingrid, primary, Superti-Furga, Giulio, primary, Snijder, Berend, primary, and Staber, Philipp B., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, primary, Vladimer, Gregory I., primary, Bayer, Günther, primary, Bergmann, Michael, primary, Eder, Sandra, primary, Eichner, Ruth, primary, Erl, Martin, primary, Esterbauer, Harald, primary, Exner, Ruth, primary, Felsleitner-Hauer, Verena, primary, Forte, Maurizio, primary, Gaiger, Alexander, primary, Geissler, Klaus, primary, Greinix, Hildegard T., primary, Gstöttner, Wolfgang, primary, Hacker, Marcus, primary, Hartmann, Bernd Lorenz, primary, Hauswirth, Alexander W., primary, Heinemann, Tim, primary, Heintel, Daniel, primary, Hoda, Mir Alireza, primary, Hopfinger, Georg, primary, Jaeger, Ulrich, primary, Kazianka, Lukas, primary, Kenner, Lukas, primary, Kiesewetter, Barbara, primary, Krall, Nikolaus, primary, Krajnik, Gerhard, primary, Kubicek, Stefan, primary, Le, Trang, primary, Lubowitzki, Simone, primary, Mayerhoefer, Marius E., primary, Menschel, Elisabeth, primary, Merkel, Olaf, primary, Miura, Katsuhiro, primary, Müllauer, Leonhard, primary, Neumeister, Peter, primary, Noesslinger, Thomas, primary, Ocko, Katharina, primary, Öhler, Leopold, primary, Panny, Michael, primary, Pichler, Alexander, primary, Porpaczy, Edit, primary, Prager, Gerald W., primary, Raderer, Markus, primary, Ristl, Robin, primary, Ruckser, Reinhard, primary, Salamon, Julius, primary, Schiefer, Ana-Iris, primary, Schmolke, Ann-Sofie, primary, Schwarzinger, Ilse, primary, Selzer, Edgar, primary, Sillaber, Christian, primary, Skrabs, Cathrin, primary, Sperr, Wolfgang R., primary, Srndic, Ismet, primary, Thalhammer, Renate, primary, Valent, Peter, primary, van der Kouwe, Emiel, primary, Vanura, Katrina, primary, Vogt, Stefan, primary, Waldstein, Cora, primary, Wolf, Dominik, primary, Zielinski, Christoph C., primary, Zojer, Niklas, primary, Simonitsch-Klupp, Ingrid, primary, Superti-Furga, Giulio, primary, Snijder, Berend, primary, and Staber, Philipp B., primary

Published
2023
Full Text
View/download PDF

8. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, additional, Vladimer, Gregory I., additional, Bayer, Günther, additional, Bergmann, Michael, additional, Eder, Sandra, additional, Eichner, Ruth, additional, Erl, Martin, additional, Esterbauer, Harald, additional, Exner, Ruth, additional, Felsleitner-Hauer, Verena, additional, Forte, Maurizio, additional, Gaiger, Alexander, additional, Geissler, Klaus, additional, Greinix, Hildegard T., additional, Gstöttner, Wolfgang, additional, Hacker, Marcus, additional, Hartmann, Bernd Lorenz, additional, Hauswirth, Alexander W., additional, Heinemann, Tim, additional, Heintel, Daniel, additional, Hoda, Mir Alireza, additional, Hopfinger, Georg, additional, Jaeger, Ulrich, additional, Kazianka, Lukas, additional, Kenner, Lukas, additional, Kiesewetter, Barbara, additional, Krall, Nikolaus, additional, Krajnik, Gerhard, additional, Kubicek, Stefan, additional, Le, Trang, additional, Lubowitzki, Simone, additional, Mayerhoefer, Marius E., additional, Menschel, Elisabeth, additional, Merkel, Olaf, additional, Miura, Katsuhiro, additional, Müllauer, Leonhard, additional, Neumeister, Peter, additional, Noesslinger, Thomas, additional, Ocko, Katharina, additional, Öhler, Leopold, additional, Panny, Michael, additional, Pichler, Alexander, additional, Porpaczy, Edit, additional, Prager, Gerald W., additional, Raderer, Markus, additional, Ristl, Robin, additional, Ruckser, Reinhard, additional, Salamon, Julius, additional, Schiefer, Ana-Iris, additional, Schmolke, Ann-Sofie, additional, Schwarzinger, Ilse, additional, Selzer, Edgar, additional, Sillaber, Christian, additional, Skrabs, Cathrin, additional, Sperr, Wolfgang R., additional, Srndic, Ismet, additional, Thalhammer, Renate, additional, Valent, Peter, additional, van der Kouwe, Emiel, additional, Vanura, Katrina, additional, Vogt, Stefan, additional, Waldstein, Cora, additional, Wolf, Dominik, additional, Zielinski, Christoph C., additional, Zojer, Niklas, additional, Simonitsch-Klupp, Ingrid, additional, Superti-Furga, Giulio, additional, Snijder, Berend, additional, and Staber, Philipp B., additional

Published
2021
Full Text
View/download PDF

9. Blood / Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter

Author

van der Kouwe, Emiel, Heller, Gerwin, Czibere, Akos, Pulikkan, John A., Agreiter, Christiane, Castilla, Lucio H., Delwel, Ruud, Di Ruscio, Annalisa, Ebralidze, Alexander K., Forte, Maurizio, Grebien, Florian, Heyes, Elizabeth, Kazianka, Lukas, Klinger, Julian, Kornauth, Christoph, Le, Trang, Lind, Karin, Barbosa, Inês Amorim Monteiro, Pemovska, Tea, Pichler, Alexander Sebastian, Schmolke, Ann-Sofie, Schweicker, Carmen Marita, Sill, Heinz, Sperr, Wolfgang R., Spittler, Andreas, Surapally, Sridevi, Trinh, Bon Q., Valent, Peter, Vanura, Katrina, Welner, Robert S., Zuber, Johannes, Tenen, Daniel G., and Staber, Philipp B.

Published
2021

10. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Author

Kornauth, Christoph, primary, Herbaux, Charles, additional, Boidol, Bernd, additional, Guillemette, Chantal, additional, Caron, Patrick, additional, Mayerhöfer, Marius E., additional, Poulain, Stéphanie, additional, Tournilhac, Olivier, additional, Pemovska, Tea, additional, Chong, Stephen J.F., additional, Van der Kouwe, Emiel, additional, Kazianka, Lukas, additional, Hopfinger, Georg, additional, Heintel, Daniel, additional, Jäger, Roland, additional, Raderer, Markus, additional, Jäger, Ulrich, additional, Simonitsch-Klupp, Ingrid, additional, Sperr, Wolfgang R., additional, Kubicek, Stefan, additional, Davids, Matthew S., additional, and Staber, Philipp B., additional

Published
2021
Full Text
View/download PDF

11. Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Author

Kornauth, Christoph, primary, Pemovska, Tea, additional, Vladimer, Gregory Ian, additional, Bayer, Günther, additional, Bergmann, Michael, additional, Eder, Sandra, additional, Eichner, Ruth, additional, Esterbauer, Harald, additional, Exner, Ruth, additional, Felsleitner-Hauer, Verena, additional, Forte, Maurizio, additional, Gaiger, Alexander, additional, Greinix, Hildegard T., additional, Gstöttner, Wolfgang, additional, Hacker, Marcus, additional, Hauswirth, Alexander, additional, Heinemann, Tim, additional, Heintel, Daniel, additional, Hoda, Mir Ali Reza, additional, Jaeger, Ulrich, additional, Kazianka, Lukas, additional, Kenner, Lukas, additional, Kiesewetter, Barbara, additional, Krall, Nikolaus, additional, Le, Trang, additional, Lubowitzki, Simone, additional, Mayerhoefer, Marius E, additional, Menschel, Elisabeth, additional, Merkel, Olaf, additional, Miura, Katsuhiro, additional, Muellauer, Leonhard, additional, Neumeister, Peter, additional, Noesslinger, Thomas, additional, Ocko, Katharina, additional, Öhler, Leopold, additional, Panny, Michael, additional, Pichler, Alexander, additional, Porpaczy, Edit Anna, additional, Prager, Gerald, additional, Raderer, Markus, additional, Ristl, Robin, additional, Ruckser, Reinhard, additional, Salamon, Julius, additional, Schiefer, Ana-Iris, additional, Schmolke, Ann-Sofie, additional, Schwarzinger, Ilse, additional, Selzer, Edgar, additional, Skrabs, Cathrin, additional, Sperr, Wolfgang R., additional, Srndic, Ismet, additional, Thalhammer, Renate, additional, Valent, Peter, additional, van der Kouwe, Emiel, additional, Vanura, Katrina, additional, Vogt, Stefan, additional, Waldstein, Cora, additional, Wolf, Dominik, additional, Zielinski, Christoph, additional, Simonitsch-Klupp, Ingrid, additional, Superti-Furga, Giulio, additional, Snijder, Berend, additional, and Staber, Philipp B., additional

Published
2020
Full Text
View/download PDF

12. Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Author

van der Kouwe, Emiel, primary, Heller, Gerwin, additional, Czibere, Akos, additional, Castilla, Lucio H., additional, Delwel, Ruud, additional, Di Ruscio, Annalisa, additional, Ebralidze, Alexander, additional, Forte, Maurizio, additional, Kazianka, Lukas, additional, Kornauth, Christoph, additional, Le, Trang, additional, Lind, Karin, additional, Barbosa, Ines, additional, Pichler, Alexander, additional, Pulikkan, John, additional, Schmolke, Ann-Sofie, additional, Sill, Heinz, additional, Sperr, Wolfgang R., additional, Spittler, Andreas, additional, Trinh, Bon Q., additional, Valent, Peter, additional, Vanura, Katrina, additional, Welner, Robert, additional, Zuber, Johannes, additional, Tenen, Daniel G., additional, and Staber, Philipp B., additional

Published
2020
Full Text
View/download PDF

14. Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML

Author

Trinh, Bon Q., primary, Ummarino, Simone, additional, Ebralidze, Alexander K., additional, van der Kouwe, Emiel, additional, Bassal, Mahmoud A., additional, Nguyen, Tuan M., additional, Coffey, Rory, additional, Tenen, Danielle E., additional, Fabiani, Emiliano, additional, Gurnari, Carmelo, additional, Wu, Chan-Shuo, additional, Angarica, Vladimir Espinosa, additional, Zhang, Yanzhou, additional, Ying, Li, additional, Yang, Henry, additional, Heller, Gerwin, additional, Chen, Sisi, additional, Zhang, Hong, additional, Thurm, Abby R., additional, Marchi, Francisco, additional, Levantini, Elena, additional, Staber, Philipp B., additional, Zhang, Pu, additional, Voso, Maria Teresa, additional, Pandolfi, Pier Paolo, additional, Ruscio, Annalisa Di, additional, and Tenen, Daniel G., additional

Published
2020
Full Text
View/download PDF

15. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Author

Boidol, Bernd, Kornauth, Christoph, van der Kouwe, Emiel, Prutsch, Nicole, Kazianka, Lukas, Gültekin, Sinan, Hoermann, Gregor, Mayerhoefer, Marius E., Hopfinger, Georg, Hauswirth, Alexander, Panny, Michael, Aretin, Marie-Bernadette, Hilgarth, Bernadette, Sperr, Wolfgang R., Valent, Peter, Simonitsch-Klupp, Ingrid, Moriggl, Richard, Merkel, Olaf, Kenner, Lukas, Jäger, Ulrich, Kubicek, Stefan, and Staber, Philipp B.

Published
2017
Full Text
View/download PDF

17. Myeloid lncRNA LOUPmediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML

Author

Trinh, Bon Q., Ummarino, Simone, Zhang, Yanzhou, Ebralidze, Alexander K., Bassal, Mahmoud A., Nguyen, Tuan M., Heller, Gerwin, Coffey, Rory, Tenen, Danielle E., van der Kouwe, Emiel, Fabiani, Emiliano, Gurnari, Carmelo, Wu, Chan-Shuo, Angarica, Vladimir Espinosa, Yang, Henry, Chen, Sisi, Zhang, Hong, Thurm, Abby R., Marchi, Francisco, Levantini, Elena, Staber, Philipp B., Zhang, Pu, Voso, Maria Teresa, Pandolfi, Pier Paolo, Kobayashi, Susumu S., Chai, Li, Di Ruscio, Annalisa, and Tenen, Daniel G.

Abstract

The mechanism underlying cell type-specific gene induction conferred by ubiquitous transcription factors as well as disruptions caused by their chimeric derivatives in leukemia is not well understood. Here, we investigate whether RNAs coordinate with transcription factors to drive myeloid gene transcription. In an integrated genome-wide approach surveying for gene loci exhibiting concurrent RNA and DNA interactions with the broadly expressed Runt-related transcription factor 1 (RUNX1), we identified the long noncoding RNA (lncRNA) originating from the upstream regulatory element of PU.1(LOUP). This myeloid-specific and polyadenylated lncRNA induces myeloid differentiation and inhibits cell growth, acting as a transcriptional inducer of the myeloid master regulator PU.1. Mechanistically, LOUPrecruits RUNX1 to both the PU.1enhancer and the promoter, leading to the formation of an active chromatin loop. In t(8;21) acute myeloid leukemia (AML), wherein RUNX1 is fused to ETO, the resulting oncogenic fusion protein, RUNX1-ETO, limits chromatin accessibility at the LOUPlocus, causing inhibition of LOUPand PU.1expression. These findings highlight the important role of the interplay between cell-type–specific RNAs and transcription factors, as well as their oncogenic derivatives in modulating lineage-gene activation and raise the possibility that RNA regulators of transcription factors represent alternative targets for therapeutic development.

Published
2021
Full Text
View/download PDF

18. Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Author

Staber, Philipp Bernhard, primary, Snijder, Berend, additional, Vladimer, Gregory Ian, additional, Krall, Nikolaus, additional, Miura, Katsuhiro, additional, Schmolke, Ann-Sofie, additional, Kornauth, Christoph, additional, Lopez de la Fuente, Oscar, additional, Choi, Hye-Soo, additional, van der Kouwe, Emiel, additional, Kazianka, Lukas, additional, Bigenzahn1, Johannes, additional, Hoermann, Gregor, additional, Prutsch, Nicole, additional, Merkel, Olaf, additional, Ringler, Anna, additional, Jeryczynski, Georg, additional, Mayerhoefer, Marius, additional, Simonitsch-Klupp, Ingrid, additional, Felberbauer, Franz X, additional, Muellauer, Leonhard, additional, Prager, Gerald W, additional, Korkmaz, Belgin, additional, Kenner, Lukas, additional, Sperr, Wolfgang R., additional, Kralovics, Robert, additional, Gisslinger, Heinz, additional, Valent, Peter, additional, Kubicek, Stefan, additional, Jaeger, Ulrich, additional, and Superti-Furga, Giulio, additional

Published
2017
Full Text
View/download PDF

19. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.

Author

Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, and Staber PB

Subjects
Adult, Aged, Aged, 80 and over, Austria, Cohort Studies, Female, Hematologic Neoplasms mortality, Humans, Male, Middle Aged, Molecular Targeted Therapy, Precision Medicine, Progression-Free Survival, Young Adult, Hematologic Neoplasms drug therapy
Abstract

Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer. A promising method may be drug profiling of patient biopsy specimens with single-cell resolution to directly quantify drug effects. We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guide treatments in 143 patients with advanced aggressive hematologic cancers. Fifty-six patients (39%) were treated according to scFPM results. At a median follow-up of 23.9 months, 30 patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease. We conclude that therapy matching by scFPM is clinically feasible and effective in advanced aggressive hematologic cancers. SIGNIFICANCE: This is the first precision medicine trial using a functional assay to instruct n-of-one therapies in oncology. It illustrates that for patients lacking standard therapies, high-content assay-based scFPM can have a significant value in clinical therapy guidance based on functional dependencies of each patient's cancer. See related commentary by Letai, p. 290 . This article is highlighted in the In This Issue feature, p. 275 ., (©2021 The Authors; Published by the American Association for Cancer Research.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results